Floatz logo

Recombinant Fowlpox-Cea/Tricom Vaccine

Stage IV Breast Cancer

National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the Stage IV Breast Cancer cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BBB
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 3BBB
Letrozole
OHSU Knight Cancer Institute
Phase 4BBB
EXEMESTANE
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Carboplatin
RenJi Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Recombinant Fowlpox-Cea/Tricom Vaccine is also rated in:

Breast CancerDormant
CC
Indicative ·
47 / 100
View asset →
Metastases, NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →
Recurrent Colon CancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →